Last Updated: November 16, 2026

Details for Patent: 7,341,744

« Back to Dashboard


Summary for Patent: 7,341,744
Title:Method of treating secretory diarrhea with enteric formulations of proanthocyanidin polymer
Abstract:Pharmaceutical compositions containing a proanthocyanidin polymer composition which are useful for the treatment and prevention of secretory diarrhea are provided. The invention specifically relates to pharmaceutical formulations of a proanthocyanidin polymer composition which has been isolated from a Croton spp. or a Calophyllum spp. In particular, the invention relates to a formulation of a proanthocyanidin polymer composition which protects the composition from the effects of stomach acid after oral administration, particularly to those formulations which are enteric coated. The invention also relates to methods of producing a directly compressible proanthocyanidin polymer composition, as well as compositions containing the directly compressible proanthocyanidin polymer composition.
Inventor(s):Edward James Rozhon, Atul S. Khandwala, Akram Sabouni, Gul P. Balwani, Jody Wai-Han Chan, David F. Sesin
Assignee: Napo Pharmaceuticals Inc
Application Number:US09/712,033
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;
Patent landscape, scope, and claims:

Scope and Claim Analysis of US Patent 7,341,744: Oral Enteric-Controlled Proanthocyanidin Polymer for Secretory Diarrhea

US Patent 7,341,744 is a U.S. method-of-treatment patent built around one active substance class (aqueous soluble proanthocyanidin polymer isolated from Croton spp. or Calophyllum spp.), one clinical target (secretory diarrhea), one administration route (oral), and one key formulation architecture (stomach protection via controlled release and/or enteric coating, including enteric-coated beads). The claim set is broad on species and patient population and narrower on the formulation type and coating chemistry.

It is not a “composition of matter” claim in the excerpt you provided. It is a method claim with defined dosing ranges, defined active source, and defined stomach-protection formulation requirements. That structure drives freedom-to-operate risk: oral dosing that uses the Croton/Calophyllum proanthocyanidin polymer and provides stomach protection can fall within the independent claim even if other excipients, tablet vs capsule selection, or patient subtypes vary, depending on which dependent limitations are met.


What does US 7,341,744 claim cover for secretory diarrhea treatment?

Short answer: The patent claims oral treatment of secretory diarrhea in humans and selected animals using an aqueous soluble proanthocyanidin polymer isolated from Croton spp. or Calophyllum spp., dosed at 0.1 to 100 mg/kg/day, with the polymer formulated to protect it from stomach conditions via controlled release and/or enteric coating, in a pharmaceutically acceptable carrier.

Independent claim 1: what must be practiced

Claim 1 requires all of the following elements to be met:

  1. Target indication

    • “Secretory diarrhea” (in animals including humans).
  2. Route

    • Oral route of administration.
  3. Patient animal universe

    • Non-human animal selected from: bovine, ovine, swine, poultry, equine, canine, feline, or a human.
  4. Dose

    • 0.1 to 100 mg/kg/day of the pharmaceutical composition.
    • Dose is specified relative to “aqueous soluble proanthocyanidin polymer composition” (not total formulation).
  5. Active substance identity

    • “Aqueous soluble proanthocyanidin polymer composition isolated from a Croton species or a Calophyllum species.”
    • This ties infringement to both source species and polymer solubility/identity (aqueous soluble proanthocyanidin polymer composition).
  6. Formulation function

    • The polymer must be formulated “to protect the aqueous soluble proanthocyanidin polymer composition from the stomach environment in a controlled release preparation.”
  7. Carrier

    • “Pharmaceutically acceptable carrier.”

Claim 1 is therefore a functional formulation requirement (“protect from the stomach environment” in controlled release), not a single fixed polymer coating material, and it does not confine the dosage form to tablets or capsules in the independent claim.

Independent claim 18 and claim 37: what changes

Claim 18 changes the formulation requirement to a more explicit architecture:

  • It requires an aqueous soluble proanthocyanidin polymer that is “coated with an enteric coating.”
  • It still requires oral administration and the 0.1 to 100 mg/kg/day range.

Claim 37 again broadens patient and animal set but uses language like claim 1: the polymer is formulated to protect from the acidic conditions of the stomach in a controlled release preparation.

Practical consequence: the independent claims create two overlapping infringement paths:

  • Controlled release stomach protection (claim 1 / claim 37),
  • Enteric coating stomach protection (claim 18).

Which specific active-source limitations matter most for scope?

Croton vs Calophyllum

The claims cover polymers isolated from either:

  • Croton species, or
  • Calophyllum species.

The dependent claim 2 and claim 19 narrow Croton to Croton lechleri.

Scope impact: A provider using proanthocyanidin polymers from non-Croton/non-Calophyllum sources can avoid the claims if the active is not within “isolated from a Croton species or Calophyllum species.” Likewise, using non-proanthocyanidin polymers, or proanthocyanidin oligomers rather than the claimed “aqueous soluble proanthocyanidin polymer composition,” creates avoidance leverage.

“Aqueous soluble proanthocyanidin polymer composition”

This is an identity constraint that can be used in litigation to dispute whether an accused product’s active material meets the definition. It is also central to claim construction:

  • “proanthocyanidin polymer composition”
  • “aqueous soluble”
  • “isolated from” the specified plant genus/species

Scope impact: even if a product contains proanthocyanidins, it may be outside the claims if its active is not the claimed “aqueous soluble proanthocyanidin polymer composition,” or not “isolated from” the claimed plant species.


What are the dose and indication boundaries in US 7,341,744?

Dose window: 0.1 to 100 mg/kg/day

All independent method claims require dosing in the 0.1 to 100 mg/kg/day window. Dependent claim 16 and claim 35 restrict further to 0.1 to 40 mg/kg/day.

Scope impact: If an accused product uses dosing outside 0.1 to 100 mg/kg/day, it avoids the independent claim. If it is within 0.1–100 but outside 0.1–40, it may still infringe independent claims but not those dependents.

Indication: secretory diarrhea

Dependent claim 8 specifies bacterium-caused secretory diarrhea; claim 9 specifies non-infectious etiology; claim 10 lists non-infectious subtypes:

  • non-specific diarrhea
  • ulcerative colitis
  • irritable bowel syndrome

Claims 12 and 30 cover:

  • HIV-Associated Chronic Diarrhea

Claim 13 and 31 cover:

  • diarrhea caused by cholera

Scope impact: The claims are framed as method-of-treatment of secretory diarrhea. If an accused use targets a different diarrhea mechanism (osmotic, inflammatory non-secretory, functional diarrhea not fitting “secretory”), it can argue non-infringement on the “secretory diarrhea” limitation.


What formulation requirements drive infringement risk: controlled release vs enteric coating?

Independent claim 1 and 37: controlled release to protect from stomach environment/acid

Claim 1 requires a controlled release formulation protecting the polymer from the stomach environment. Claim 37 adds “acidic conditions of the stomach.”

Claim 1 does not require:

  • a specific enteric polymer chemistry,
  • a beads structure,
  • a tablet vs capsule form.

So claim 1 reads on many oral stomach-protecting approaches so long as the polymer is “protected” from stomach conditions in a controlled release preparation.

Independent claim 18: explicit enteric-coated polymer

Claim 18 requires the polymer to be coated with an enteric coating.

This typically increases proof burden for an accused infringer (presence of an enteric-coated active or particles), but it is also a clearer infringement theory than “controlled release” alone.

Enteric coating chemistry in dependent claim 20

Dependent claim 20 specifies:

  • methacrylic acid-methacrylic acid ester copolymer with acid ionizable groups.

Scope impact: claim 20 only applies to products whose enteric coating is that copolymer. Products using other enteric coating materials could avoid claim 20 while still potentially infringing claim 18 if they meet the enteric-coating requirement broadly.

Dosage forms: tablets and enteric-coated capsules

Dependent claim 3 and claim 21 cover compressed tablets.

Dependent claim 6 and claim 24 cover:

  • enteric coated capsule
  • capsule containing beads with a core (polymer) and a layer (enteric coating).

Scope impact: The independent claims do not require beads or a capsule. However, the beads architecture can be used to map infringement across particle-based enteric delivery designs.

Lubricant limitation: magnesium stearate

Dependent claim 4/22 restrict tablet formulations to those with magnesium stearate.

Scope impact: This is narrow. It likely matters only for tablet designs and only if an infringer’s lubricant/excipient package omits magnesium stearate.

Animal feed administration: claim 15 and claim 34

Claim 15 and claim 34 allow the animal administration route:

  • “administered in animal feed.”

Scope impact: This materially broadens infringement scenarios into veterinary and livestock product manufacturing, including mixing/providing the composition in feed.


How broad is the claim set versus common competitive design-arounds?

Main infringement “tripwires”

A product is at high risk if it checks these boxes simultaneously:

  • active is an aqueous soluble proanthocyanidin polymer isolated from Croton spp. or Calophyllum spp.
  • used to treat secretory diarrhea (as understood clinically and legally)
  • administered orally at 0.1 to 100 mg/kg/day
  • formulated to protect from stomach environment/acid via controlled release or enteric coating
  • includes pharmaceutically acceptable carrier

Likely carve-outs

  1. Source change: using proanthocyanidin polymers from other botanical sources.
  2. Formulation change: using oral dosing without adequate stomach protection such that it does not “protect from the stomach environment” in a controlled release preparation, and/or not enteric coated.
  3. Dose change: dosing outside 0.1–100 mg/kg/day.
  4. Indication change: not claiming or instructing for secretory diarrhea (especially if marketed for non-secretory diarrhea mechanisms).
  5. Patient population change: while the independent claim covers animals and humans, sub-features like infants/children, HIV-associated chronic diarrhea, or cholera are dependent limitations. But the risk remains under independent coverage if the product targets secretory diarrhea generally.

Claim-by-claim scope map (what each dependent claim adds)

Claims 2, 19 (Croton lechleri)

  • Adds a plant species specificity.

Claims 3, 21 (compressed tablet)

  • Adds dosage form.

Claims 4, 22 (lubricant required)

  • Adds formulation component requirement.

Claims 5, 23 (magnesium stearate)

  • Narrows lubricant to magnesium stearate.

Claims 6, 24 (enteric-coated capsule)

  • Adds dosage form and enteric-coated status.

Claims 7, 25 (beads in capsule)

  • Adds bead core + enteric coating architecture.

Claims 8, 26 (bacterial etiology)

  • Adds an etiology subgroup.

Claims 9, 27 (non-infectious etiology)

  • Adds an etiology subgroup.

Claims 10, 28 (non-infectious subtypes)

  • Adds explicit disease examples (non-specific diarrhea, ulcerative colitis, IBS).

Claims 11, 29 (infant/child)

  • Adds pediatric subgroup.

Claims 12, 30 (HIV-associated chronic diarrhea)

  • Adds specific disease context.

Claims 13, 31 (cholera diarrhea)

  • Adds specific disease context.

Claims 14, 32, 33 (animal treatment and animal set)

  • Adds animal-only variations and enumerates species set.

Claims 15, 34 (animal feed)

  • Adds administration mode for veterinary use.

Claims 16, 35 (0.1 to 40 mg/kg/day)

  • Narrows dose window further.

Claims 17, 36 (carrier)

  • Adds/clarifies carrier presence; likely assumed in construction but used as a dependent recitation.

Claim 18 (enteric coating on active/polymers)

  • Independent formulation path: explicit enteric coating of the polymer.

Claim 20 (enteric coating chemistry)

  • Narrows enteric polymer.

What is the practical infringement theory: method performance vs product supply?

US 7,341,744 is drafted as method of treatment. That typically raises infringement questions around:

  • whether a manufacturer’s activities and labeling induce the performance of the claimed method,
  • whether prescribing and administering by clinicians/veterinarians satisfies the method steps,
  • and whether the formulation is the one that provides stomach protection as claimed.

Because the independent claims require a specific dose and stomach-protection formulation, infringement in practice hinges on whether the end-user (prescriber/manufacturer under instructions) administers the accused oral controlled-release/enteric product at the specified mg/kg/day range for secretory diarrhea.


How do these claims compare with common patent landscape patterns in GI antidiarrheals?

Method claims like this often coexist with:

  • composition patents on the active extract or purified polymer,
  • formulation patents (enteric coating, sustained release matrix, particle engineering),
  • and manufacturing patents.

In US 7,341,744, the claim architecture pushes coverage toward:

  • active botanical provenance (Croton/Calophyllum)
  • drug product delivery (controlled release/enteric coating, beads)
  • mechanistic clinical framing (secretory diarrhea, etiology subcategories)

This is narrower than a broad “use of proanthocyanidin polymers for diarrhea” patent because it anchors to source species, aqueous soluble polymer identity, and stomach-protection formulation function.


What exclusivity and generic entry risks flow from a method-of-treatment patent?

Key point: Even if a generic or biosimilar is approved for an active ingredient, a method-of-treatment patent can still block or constrain market entry if:

  • the generic’s instructions or packaging encourage infringing dosing and use, and
  • the product’s formulation satisfies stomach-protection requirements.

For challenge pathways:

  • A Paragraph IV filing would typically need a basis that the method patent is invalid, unenforceable, or not infringed by the proposed generic’s label and product.
  • Since the claim requires explicit dose mg/kg/day and formulation stomach protection, a label carve-out or formulation design change can be used to argue no infringement, but only if the carve-out is consistent with the therapeutic dosing regimen and the actual product characteristics.

Because the claims also include dependent disease-context limitations (HIV-associated chronic diarrhea, cholera), a label that is limited to other diarrhea subtypes could reduce infringement exposure relative to a broad secretory diarrhea indication, but the independent claim can still be asserted if the proposed product is used to treat secretory diarrhea generally.


Which claim features should be prioritized for freedom-to-operate mapping?

  1. Active identity and provenance

    • Croton/Calophyllum source and “aqueous soluble proanthocyanidin polymer composition” definition.
  2. Stomach protection mechanism

    • controlled release that protects from stomach environment/acid vs enteric coating.
  3. Oral dosing

    • 0.1–100 mg/kg/day dosing in the method.
  4. Intended use and instructions

    • labeling aligned to secretory diarrhea treatment.
  5. Dosage form architecture

    • tablet vs capsule; beads vs non-beads; enteric coating presence.
  6. Veterinary channel

    • whether use is in animal feed.

Key Takeaways

  • US 7,341,744 is a method-of-treatment patent with independent claims anchored to oral dosing of an aqueous soluble proanthocyanidin polymer isolated from Croton spp. or Calophyllum spp. for secretory diarrhea, with 0.1 to 100 mg/kg/day dosing and stomach-protecting controlled release or enteric-coated formulation requirements.
  • Independent claim 1/37 are broader on formulation mechanics (“protect from stomach environment/acid” in controlled release). Independent claim 18 is clearer and narrower on enteric-coated polymers.
  • Dependent claims add incremental scope constraints on Croton lechleri, enteric-coated capsule/beads, tablet/lubricant, and specific etiologies (bacterial, non-infectious including IBS/ulcerative colitis), plus specific clinical contexts (HIV-associated chronic diarrhea, cholera) and pediatric subpopulation.
  • The main design-around levers are: change botanical source, change active identity/form, eliminate stomach-protecting formulation function, and/or move dose outside 0.1–100 mg/kg/day, with secondary leverage from labeling/indication strategy for secretory diarrhea.

FAQs

1) Does US 7,341,744 require an enteric coating to infringe?
No. Independent claim 1 and claim 37 require controlled release protection from the stomach environment/acid, while claim 18 explicitly requires an enteric coating.

2) If an accused product uses Croton lechleri, does it automatically infringe?
Not automatically. Infringement still requires oral administration to treat secretory diarrhea at 0.1–100 mg/kg/day using a formulation that protects the polymer from stomach conditions as claimed.

3) Can a product avoid the patent by changing tablet excipients like magnesium stearate?
Avoiding the lubricant-dependent claims (e.g., magnesium stearate) is possible, but the independent claims can still be implicated if all core elements are met.

4) How does animal feed administration affect infringement exposure?
It expands the method performance context beyond human prescriptions to veterinary feed administration, aligning with dependent claims 15 and 34.

5) Do claims targeting HIV-associated chronic diarrhea or cholera provide additional independent coverage?
No. Those are dependent limitations. They add narrower infringement theories, but the independent secretory-diarrhea method claims remain broader.


References

  1. United States Patent 7,341,744. “Method of treatment for secretory diarrhea in animals, including humans,” claims as provided in the prompt.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 7,341,744

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,341,744

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 430477 ⤷  Start Trial
Australia 2030302 ⤷  Start Trial
Australia 4988197 ⤷  Start Trial
Australia 775330 ⤷  Start Trial
Canada 2269078 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.